Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination

Abstract

BACKGROUND: Recent Mycobacterium tuberculosis infection confers a predisposition to the development of tuberculosis disease, the leading killer among global infectious diseases. H4:IC31, a candidate subunit vaccine, has shown protection against tuberculosis disease in preclinical models, and observational studies have indicated that primary bacille Calmette-Guérin (BCG) vaccination may offer partial protection against infection. METHODS: In this phase 2 trial, we randomly assigned 990 adolescents in a high-risk setting who had undergone neonatal BCG vaccination to receive the H4:IC31 vaccine, BCG revaccination, or placebo. All the participants had negative results on testing for M. tuberculosis infection on the QuantiFERON-TB Gold In-tube assay (QFT) and for the human immunodeficiency virus. The primary outcomes were safety and acquisition of M. tuberculosis infection, as defined by initial conversion on QFT that was performed every 6 months during a 2-year period. Secondary outcomes were immunogenicity and sustained QFT conversion to a positive test without reversion to negative status at 3 months and 6 months after conversion. Estimates of vaccine efficacy are based on hazard ratios from Cox regression models and compare each vaccine with placebo. RESULTS: Both the BCG and H4:IC31 vaccines were immunogenic. QFT conversion occurred in 44 of 308 participants (14.3%) in the H4:IC31 group and in 41 of 312 participants (13.1%) in the BCG group, as compared with 49 of 310 participants (15.8%) in the placebo group; the rate of sustained conversion was 8.1% in the H4:IC31 group and 6.7% in the BCG group, as compared with 11.6% in the placebo group. Neither the H4:IC31 vaccine nor the BCG vaccine prevented initial QFT conversion, with efficacy point estimates of 9.4% (P=0.63) and 20.1% (P=0.29), respectively. However, the BCG vaccine reduced the rate of sustained QFT conversion, with an efficacy of 45.4% (P=0.03); the efficacy of the H4:IC31 vaccine was 30.5% (P=0.16). There were no clinically significant between-group differences in the rates of serious adverse events, although mild-to-moderate injection-site reactions were more common with BCG revaccination. CONCLUSIONS: In this trial, the rate of sustained QFT conversion, which may reflect sustained M. tuberculosis infection, was reduced by vaccination in a high-transmission setting. This finding may inform clinical development of new vaccine candidates. (Funded by Aeras and others; C-040-404 ClinicalTrials.gov number, NCT02075203 .).

Shown for reading. Its publisher allows quoting it, not republishing it.

References 37

1. 1.

   WHO. Global tuberculosis report 2017.

   Not in our library

2. 2.

   Knight GM, Griffiths UK, Sumner T, et al. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci U S A 2014;111:15520-5.

   Not in our library10.1073/pnas.1404386111

3. 3.

   Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers 2016;2:16076.

   Not in our library10.1038/nrdp.2016.76

4. 4.

   Hawn TR, Day TA, Scriba TJ, et al. Tuberculosis vaccines and prevention of infection. Microbiol Mol Biol Rev 2014;78:650-71.

   Not in our library10.1128/mmbr.00021-14

5. 5.

   Ellis RD, Hatherill M, Tait D, et al. Innovative clinical trial designs to rationalize TB vaccine development. Tuberculosis (Edinb) 2015;95:352-7.

   Not in our library10.1016/j.tube.2015.02.036

6. 6.

   Hatherill M, Tait D, McShane H. Clinical Testing of Tuberculosis Vaccine Candidates. Microbiol Spectr 2016;4.

   Not in our library10.1128/microbiolspec.tbtb2-0015-2016

7. 7.

   Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 2014;27:3-20.

   Not in our library10.1128/cmr.00034-13

8. 8.

   Nemes E, Rozot V, Geldenhuys H, et al. Optimization and interpretation of serial QuantiFERON testing to measure acquisition of Mycobacterium tuberculosis Infection. Am J Respir Crit Care Med 2017;196:638-48.

   Not in our library10.1164/rccm.201704-0817oc

9. 9.

   Mahomed H, Hawkridge T, Verver S, et al. The tuberculin skin test versus QuantiFERON TB Gold in predicting tuberculosis disease in an adolescent cohort study in South Africa. PLoS One 2011;6:e17984.

   Not in our library10.1371/journal.pone.0017984

10. 10.

    Machingaidze S, Verver S, Mulenga H, et al. Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents. Am J Respir Crit Care Med 2012;186:1051-6.

    Not in our library10.1164/rccm.201206-1134oc

11. 11.

    Andrews JR, Hatherill M, Mahomed H, et al. The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents. Am J Respir Crit Care Med 2015;191:584-91.

    Not in our library10.1164/rccm.201409-1704oc

12. 12.

    Riley RL, Mills CC, Nyka W, et al. Aerial dissemination of pulmonary tuberculosis. A two-year study of contagion in a tuberculosis ward. 1959. Am J Epidemiol 1995;142:3-14.

    Not in our library10.1093/oxfordjournals.aje.a117542

13. 13.

    Dahlstrom A. The instability of the tuberculin reaction. Am Rev Tuberc 1940;42:471-87.

    Not in our library

14. 14.

    Dharmadhikari AS, Basaraba RJ, Van Der Walt ML, et al. Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis. Tuberculosis (Edinb) 2011;91:329-38.

    Not in our library10.1016/j.tube.2011.03.002

15. 15.

    Soysal A, Millington KA, Bakir M, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 2005;366:1443-51.

    Not in our library10.1016/s0140-6736(05)67534-4

16. 16.

    Eisenhut M, Paranjothy S, Abubakar I, et al. BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. Vaccine 2009;27:6116-20.

    Not in our library10.1016/j.vaccine.2009.08.031

17. 17.

    Basu Roy R, Sotgiu G, Altet-Gomez N, et al. Identifying predictors of interferon- gamma release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Guerin?: a pTB-NET collaborative study. Am J Respir Crit Care Med 2012;186:378-84.

    Not in our library10.1164/rccm.201201-0026oc

18. 18.

    Roy A, Eisenhut M, Harris RJ, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ 2014;349:g4643.

    Not in our library10.1136/bmj.g4643

19. 19.

    Dye C. Making wider use of the world's most widely used vaccine: Bacille Calmette- Guerin revaccination reconsidered. J R Soc Interface 2013;10:20130365.

    Not in our library10.1098/rsif.2013.0365

20. 20.

    Barreto ML, Pereira SM, Pilger D, et al. Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG- REVAC cluster-randomised trial. Vaccine 2011;29:4875-7.

    Not in our library10.1016/j.vaccine.2011.05.023

21. 21.

    Rodrigues LC, Pereira SM, Cunha SS, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster- randomised trial. Lancet 2005;366:1290-5.

    Not in our library10.1016/s0140-6736(05)67145-0

22. 22.

    Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet 1996;348:17-24.

    Not in our library

23. 23.
    Protection and Polyfunctional T Cells Induced by Ag85B-TB10.4/IC31® against Mycobacterium tuberculosis Is Highly Dependent on the Antigen Dose · 2009

    No notice
24. 24.

    Elvang T, Christensen JP, Billeskov R, et al. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS One 2009;4:e5139.

    Not in our library10.1371/journal.pone.0005139

25. 25.

    Billeskov R, Elvang TT, Andersen PL, Dietrich J. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One 2012;7:e39909.

    Not in our library10.1371/journal.pone.0039909

26. 26.

    Geldenhuys H, Mearns H, Miles DJ, et al. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial. Vaccine 2015;33:3592-9.

    Not in our library10.1016/j.vaccine.2015.05.036

27. 27.

    Norrby M, Vesikari T, Lindqvist L, et al. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials. Vaccine 2017;35:1652-61.

    Not in our library10.1016/j.vaccine.2017.01.055

28. 28.

    Joint review of HIV, TB and PMTCT programmes in South Africa: Department of Health, Republic of South Africa; 2014.

    Not in our library

29. 29.

    Graves AJ, Padilla MG, Hokey DA. OMIP-022: Comprehensive assessment of antigen-specific human T-cell functionality and memory. Cytometry A 2014;85:576-9. 30. Andrews JR, Nemes E, Tameris M, et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respir Med 2017;5:282-90.

    Not in our library10.1016/s2213-2600(17)30060-7

30. 30.

    Andrews JR, Nemes E, Tameris M, et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respir Med 2017;5:282-90.

    Not in our library10.1016/s2213-2600(17)30060-7

31. 31.

    Hatherill M, Geldenhuys H, Pienaar B, et al. Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults. Vaccine 2014;32:3982-8.

    Not in our library10.1016/j.vaccine.2014.04.084

32. 32.

    Andersen P, Doherty TM, Pai M, Weldingh K. The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med 2007;13:175-82.

    Not in our library10.1016/j.molmed.2007.03.004

33. 33.

    Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 2014;58:470-80.

    Not in our library10.1093/cid/cit790

34. 34.

    Abubakar I, Pimpin L, Ariti C, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis. Health Technol Assess 2013;17:1-372, v-vi.

    Not in our library10.3310/hta17370

35. 35.

    Ponnighaus JM, Fine PE, Sterne JA, et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 1992;339:636-9.

    Not in our library10.1016/0140-6736(92)90794-4

36. 36.

    Lin PL, Ford CB, Coleman MT, et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med 2014;20:75- 9.

    Not in our library10.1038/nm.3412

37. 37.

    Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. Nat Rev Immunol 2017;17:691-702.

    Not in our library10.1038/nri.2017.69

Cited by papers we hold 12

• Vaccine adjuvants: mechanisms and platforms · 2023
  No notice
• End-point definition and trial design to advance tuberculosis vaccine development · 2022
  Not checked
• COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa · 2021
  Not checked
• A 2-Dose AERAS-402 Regimen Boosts CD8+ Polyfunctionality in HIV-Negative, BCG-Vaccinated Recipients · 2021
  Not checked
• TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases · 2021
  No notice
• Robust IgM responses following intravenous vaccination with Bacille Calmette–Guérin associate with prevention of Mycobacterium tuberculosis infection in macaques · 2021
  No notice
• Single cell analysis of M. tuberculosis phenotype and macrophage lineages in the infected lung · 2021
  No notice
• Adaption of the ex vivo mycobacterial growth inhibition assay for use with murine lung cells · 2020
  Not checked
• β-Glucan Induces Protective Trained Immunity against Mycobacterium tuberculosis Infection: A Key Role for IL-1 · 2020
  Not checked
• Therapeutic host-directed strategies to improve outcome in tuberculosis · 2020
  No notice
• M. tuberculosis Reprograms Hematopoietic Stem Cells to Limit Myelopoiesis and Impair Trained Immunity · 2020
  No notice
• IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure · 2019
  Corrected

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.